Colorectal Cancer

Certain patient-reported outcomes including fatigue and emotional support are associated with survival outcomes in patients with early-stage colorectal cancer.

Advanced colorectal cancer patients with BRAF mutations have markedly worse prognosis than non-mutant patients, according to a large analysis. Post-progression survival in particular is worse among BRAF-mutant patients.

Patients with metastatic colorectal cancer who engaged in more hours of physical activity at the time of their diagnosis had improvements in both progression-free and overall survival compared with patients who had less physical activity.

Non-aspirin NSAIDs are more effective than other options for colorectal chemoprevention in individuals with previous colorectal neoplasia, according to a new meta-analysis. Low-dose aspirin, however, is a safer option, and offers the best risk-benefit profile.

More than 15% of patients with early-onset colorectal cancer may harbor mutations to cancer susceptibility genes, suggesting a need for genetic counseling and a multigene panel.

A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks.

In the United States, approximately 20% of patients with colorectal cancer present with distant metastasis at diagnosis. In 25% of cases, the peritoneal cavity is the only site of metastatic disease, which is not indicative of a generalized systemic disease, as is the case with lung or liver metastases.

The occurrence of colon cancer on the right vs left side of the colon is a prognostic factor for all stages of the disease.

Patients with peritoneal metastatic colorectal cancer had significantly shorter overall survival compared with patients with other isolated sites of metastases.

The expansion of healthcare in Massachusetts in 2006 was associated with increased rates of resection for patients with colorectal cancer.

Colonoscopy screening is modestly effective for preventing colorectal cancer in patients aged 70 to 74, but the benefits may begin to diminish after that.

If you’ve been in oncology long enough, you’ve likely seen the patient who presents with metastatic disease, gets first-line therapy, progresses, switches to second-line therapy, progresses again, and so on, with their cancer becoming increasingly more resistant to therapy.

A set of genes that are more likely to be mutated in African-Americans vs Caucasians with colorectal cancer appears to increase the risk of metastases and relapse in mutant versions.

In this interview we discuss the GeneFx Colon test (or the ColDx assay), which can helpful identify patients with low- or high-risk stage II colon cancer.

A gene expression microarray-based assay was able to successfully identify patients with stage II colon cancer who are at high risk for recurrence.

A study found that fusobacteria, commonly found in the mouth, can enrich colorectal cancer cells, in a process mediated by the Fap2 protein.

Circulating tumor DNA detected after resection of stage II colon cancer appears to identify patients who are at high-risk of tumor recurrence.

Combination treatment with the MEK inhibitor cobimetinib and the anti–PD-L1 drug atezolizumab was active in patients with microsatellite-stable metastatic colorectal cancer.

The USPSTF has issued an updated guideline with recommendations regarding screening for colorectal cancer. A systematic review found that screening can be of “substantial net benefit.”

Here we discuss the evolution of standard therapy for rectal cancer patients and the use of preoperative CRT for the treatment of locally advanced disease. Treatment schemes that have attempted to broaden the horizons of standard therapy include the use of induction chemotherapy and “watch-and-wait” approaches.

By adjusting the sequencing of currently available treatments, improved compliance with therapy is ensured, and novel scientific and clinically relevant hypotheses can be further explored.

In this interview we discuss the CheckMate 142 trial, which looked at nivolumab and ipilimumab for the treatment of metastatic colorectal cancer.

Matching targeted therapies to genetic abnormalities harbored by tumor types for which those therapies are not approved by the FDA might expand treatment options for some patients with advanced cancers.

The physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer, according to an analysis to be presented at ASCO.

Combined therapy with trastuzumab and the tyrosine kinase inhibitor lapatinib shows promise against chemotherapy-refractory, HER2-positive colorectal cancers that do not harbor KRAS mutations.